\n \n \n \n \n \n \n

____________________<\/span><\/p> <\/td> \n <\/tr> \n

^{1<\/sup> Performance data based on updated CE Mark and WHO EUL submission<\/span><\/p> <\/td> \n <\/tr> \n}

^{2<\/sup> Poh CM et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralizing antibodies in COVID-19 patients. Nat Commun 2020;11(1):2806. doi:10.1038\/s41467-020-16638-2<\/span><\/p> <\/td> \n <\/tr> \n}

^{3<\/sup> Keech C, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med Accepted manuscript. Published online September 2, 2020. doi:10.1056\/NEJMoa2026920<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
\n}

Logo - https:\/\/mma.prnasia.com\/media2\/271488\/Abbott_Logo.jpg?p=medium600<\/a> <\/p>"]; $("#dvExtra").html(content_array[0]);})();